Larimar Therapeutics Inc (LRMR NASDAQ) stock market data APIs
$3.296
-0.07(-2.1%)
as of July 8, 2025
Try our APIs with
free plan!
Larimar Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Prev. Close
3.296
Open
3.2235
High
3.4504
Low
3.2235
52 wk Range
1.61-11.2
Market Cap
213 M
Shares Outstanding
64 028 K
EPS
-0.46
Beta
0.79
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Larimar Therapeutics Inc data using free add-ons & libraries
Get Larimar Therapeutics Inc Fundamental Data
Larimar Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -105 018 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.4091
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Larimar Therapeutics Inc News
New
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submi...
Larimar Therapeutics soars 70% after April fair value signal
Investing.com’s Fair Value analysis has once again demonstrated its effectiveness in identifying undervalued opportunities, with Larimar Therapeutics (NASDAQ:LRMR) delivering a remarkable 70% return...
Guggenheim reiterates buy rating on Larimar stock citing FDA path clarity
Investing.com - Guggenheim maintained its Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ:LRMR) following management meetings in New York. The firm highlighted that FDA safety requ...
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
